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Abstract
Four-and-a-half LIM domain protein 1 isoform A (FHL1A) is predominantly expressed in skeletal and cardiac muscle.
Mutations in the FHL1 gene are causative for several types of hereditary myopathies including X-linked myopathy with
postural muscle atrophy (XMPMA). We here studied myoblasts from XMPMA patients. We found that functional FHL1A
protein is completely absent in patient myoblasts. In parallel, expression of FHL1C is either unaffected or increased.
Furthermore, a decreased proliferation rate of XMPMA myoblasts compared to controls was observed but an increased
number of XMPMA myoblasts was found in the G0/G1 phase. Furthermore, low expression of Kv1.5, a voltage-gated
potassium channel known to alter myoblast proliferation during the G1 phase and to control repolarization of action
potential, was detected. In order to substantiate a possible relation between Kv1.5 and FHL1C, a pull-down assay was
performed. A physical and direct interaction of both proteins was observed in vitro. In addition, confocal microscopy
revealed substantial colocalization of FHL1C and Kv1.5 within atrial cells, supporting a possible interaction between both
proteins in vivo. Two-electrode voltage clamp experiments demonstrated that coexpression of Kv1.5 with FHL1C in Xenopus
laevis oocytes markedly reduced K
+ currents when compared to oocytes expressing Kv1.5 only. We here present the first
evidence on a biological relevance of FHL1C.
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Introduction
LIM, an acronym of three homeodomain-containing transcrip-
tion factors (Lin-11, Isl-1, and Mec-3), contains a 50–60 amino
acid stretch and a highly conserved, double cysteine-rich Zink-
finger domain. LIM domain-containing proteins play important
roles in various cellular processes, such as cytoskeleton organiza-
tion, signal transduction, gene expression and cell differentiation
[1,2]. Four and a half LIM protein 1 (FHL1) is a main
representative of the LIM-only protein family that is characterized
by a half LIM domain (located in the N-terminal portion) and four
additional complete LIM domains stretching towards the C-
terminal portion. FHL1 is suggested to play a role in sarcomere
synthesis and assembly [3]. Overexpression of FHL1 in mouse
skeletal muscle promotes myocardial fusion and hypertrophy,
observations with potential implications for human myopathy [4].
In humans, FHL1 is predominantly expressed in skeletal muscle
and heart, but also in other tissues e.g. brain, placenta, lung, liver
and kidney, at a lower abundance.
In addition to the prevalently expressed FHL1A protein (280
amino acids) two minor splice variants, originally identified from
murine studies, exist. FHL1B (323 amino acids, the homolog of
murine KyoT3 and specifically expressed in brain [5]) comprises
the N-terminal three and a half LIM domains and a unique C-
terminus containing three nuclear localization signals, a nuclear
export sequence, and a C-terminal binding site for RBP-Jk.
FHL1C (194 amino acids, the homolog of murine KyoT2)
contains the N-terminal two and a half LIM domains and the C-
terminal binding site for RBP-Jk (Figure 1).
Several mutations in the human FHL1 gene are associated with
severe or less severe types of hereditary muscular dystrophies and
myopathies [2,6–11]. The majority of these FHL1 mutations are
located in the second LIM domain of FHL1A. A specific mutation
in the fourth LIM domain in the FHL1A gene as occurring is
associated with X-linked myopathy with postural muscle atrophy
(XMPMA, MIM ID #300696). This disease is characterized by
atrophy of postural muscles with rigid spine syndrome, pseudo
athleticism or hypertrophy and hypertrophic cardiomyopathy [6].
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from two XMPMA patients with different mutations in FHL1A.
The classical missense mutation c.672C.G (on protein level
p.C224W) leads to disruption of the fourth LIM domain in
FHL1A and subsequent degradation of the protein due to the loss
of one cysteine-rich Zink-finger domain; in parallel expression of
endogenous FHL1C remains unaffected [6]. The second, a splice
site mutation c.688+1G.A (on protein level p.G168fs), results in
the deletion of two C-terminal LIM domains in FHL1A; the
resulting truncated FHL1-like protein is identical to FHL1C
(Figure 1); as a consequence, concentrations of FHL1C (the sum of
endogenous and truncated FHL1-like protein) should increase [9].
FHL1C is specifically expressed in testis, skeletal muscle, and heart
at a relatively low level compared to FHL1A [12]; however, to
date FHL1C is still considered a protein of unknown function.
Recent evidence suggested that the voltage-gated potassium
channel Kv1.5 could act as a binding partner for LIM-domain
containing proteins [13]. In myoblasts, cell cycle-dependent
expression of Kv1.5 has been reported [14]. Kv1.5 plays a role in
myocardial repolarisation and may regulate skeletal muscle
proliferation [14,15]. Furthermore, Kv1.5 forms the major basis
of an atrial-specific ultra-rapid delayed rectifier potassium ion
current IKur [16] and most importantly, a missense mutation in
Kv1.5 can result in atrial fibrillation [17]. Therefore, the second
aim of this study was to clarify whether Kv1.5 is expressed in
XMPMA myoblasts and whether this K
+ channel could act as a
specific binding partner for FHL1C. We further investigated
whether FHL1C and Kv1.5 colocalize in cellular compartments.
Using a pull-down assay we then tried to reveal a direct interaction
between both proteins. Finally, electrophysiological studies were
performed, aiming to test whether FHL1C functionally interacts
with Kv1.5.
Materials and Methods
Cell culture
(i) Human myoblast cultures were established from muscle
biopsies of two male unaffected controls (termed WT1 and WT2)
and two male XMPMA patients with either the missense mutation
p.C224W (termed MUT1) or the splice mutation p.G168fs
(termed MUT2) (Figure 1). Clinical characteristics and histological
examinations in addition to molecular genetics of MUT1 and
MUT2 patients are described in detail in reference [9]. The ethic
board of the Ludwig-Maximilians University, Munich, Germany,
gave ethical approval. All patients gave their written informed
consent to scientific analyses of their blood samples and myoblasts.
Tissue sources for myoblast isolation were tibialial anterior
muscle biopsy (WT1 and MUT1) and a biceps brachii muscle
biopsy (WT2 and MUT2). Myoblasts were grown in skeletal
muscle cell growth medium (PromoCell GmbH, Heidelberg,
Germany) including supplement mix containing 10% (v/v) FCS
(Invitrogen, Lofer, Austria), 1.5% (v/v) 1006Glutamax, 50 ml/ml
gentamycin. Myoblasts isolated from controls and XMPMA
patients consisted of a homogenous cell population and were
confirmed to be of satellite origin (using a specific antibody raised
human neuronal cell adhesion molecule, clone 123C3, Monosan,
Uden, The Netherlands).
(ii) HL-1, established from the AT-1 mouse atrial cardiomyocyte
cell line, was used for cotransfection experiments [18]. Cells were
grown in Claycomb medium (Fluka, Sigma Aldrich, Munich,
Germany) including 10% (v/v) FCS at 37uC (5% CO2, 95% air,
relative humidity of 95%).
Myoblast proliferation assay
Myoblasts (2610
5 cells, 40% confluence) were seeded in six-well
plates at a density of 2.7610
4/cm
2 cultured up to 96 h in skeletal
muscle cell growth medium (including a supplement mix
containing 10% [v/v] FCS, 1.5% [v/v] 1006 Glutamax, 50 ml/
ml gentamycin). Cells were harvested after 24, 48, 72 and 96 h
using 0.25% (v/v) trypsin. Cell proliferation was determined by
measuring the number of viable cells at the indicated time periods
using a cell counter and analyser system CASYHModel TT (Roche
Innovatis AG, Bielefeld, Germany) as described [19].
Cell cycle analysis by flow cytometry
Myoblasts were seeded in six-well plates at a density of 2.7610
4
cells/cm
2 and cultured for 48 h, collected in PBS and centrifuged
5 min at 200 g. Cells were resuspended in 0.5 ml PBS and fixed in
ice-cold 70% ethanol overnight. Thereafter, 0.25% (w/v) pepsin
Figure 1. Wild-type FHL1 protein isoforms and mutated FHL1A
proteins. Top: FHL1A, FHL1B and FHL1C protein structures (resulting
from alternative splicing of the wild-type FHL1 gene), including the LIM
domain architecture and functional domains (RBP-Jk, recombination
signal-binding protein 1 for J-kappa; NLS, nuclear localization signals;
NES, nuclear export sequence) are shown for the corresponding
variants. Bottom: Protein structures resulting from alternative splicing
of the two different mutant FHL1 genes. An arrow in the fourth LIM
domain of mutated FHL1A at position 224 (termed FHL1A
p.C224W)
indicates the position of the amino acid exchange. The dotted line
suggests alterations in the LIM-like architecture (termed MUT1 here).
FHL1A
p.G168fs is identical to FHL1C protein (termed MUT2 here)
(G=glycine, fs=frame shift).
doi:10.1371/journal.pone.0026524.g001
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Samples were kept for 30 min at 4uC in the dark. Flow cytometric
measurements were carried out using CyFlowH flow cytometer
(Partec) according to the manufacturer’s suggestions. For data
analysis MultiCycleAV DNA cell cycle analysis software (Phoenix,
San Diego, CA, USA) was used.
RNA isolation and reverse transcription PCR
Myoblasts (2610
5 cells) were seeded in six-well plates, cultured
for 48 h and harvested by treatment with 0.25% (v/v) trypsin. TRI
Reagent (Invitrogen) was used for total RNA isolation according to
the manufacturer’s suggestions.
Final RNA concentrations were measured by Nanodrop
technique (Thermo Scientific). Reverse transcription was per-
formed from two mg of total RNA with random hexamer primers
and SuperScript III Reverse Transcriptase (RT) (Invitrogen)
[20,21]. PCR primers (Table S1) were used to amplify the
corresponding PCR products for FHL1 and Kv1.5. To ensure
equal RNA loading, RT-PCR for human hypoxanthine phos-
phoribosyltransferase was performed for each experiment. Two
control reactions (RNA template without primers and a water
template only) were included in the absence of cDNA.
Protein isolation and Western blotting
Myoblasts were cultured and trypsinized as described above.
The cells were washed with HBSS buffer, mixed with lysis buffer
(0.1 M Tris pH 7.4, 10% [v/v] SDS, 0.1 M Na3VO4, 0.5 M NaF,
0.1 M sodium pyrophosphate buffer) and heated at 95uC for
10 min. Total cell lysate was frozen and stored at 220uC until use.
Protein concentrations were measured with the Bradford Protein
Assay Kit (Bio-Rad, Vienna, Austria). Aliquots of proteins were
supplemented with NuPageH LDS sample buffer and NuPageH
sample reducing agent (5%, v/v). After boiling for 5 min at 95uC,
protein samples were subjected to electrophoresis at 4–12%
NuPageH gradient SDS-PAGE gels [22] and transferred (90 min,
200 mA) to nitrocellulose membranes (0.45 mm, Schleicher and
Schuell, Dassel, Germany, [23]). The membranes were blocked
(30 min) with TBST (10 mM Tris-HCl [pH 7.4], 140 mM NaCl,
0.1% [v/v] Tween-20) containing 3% (w/v) non-fat dry milk
followed by incubation overnight at 4uC with polyclonal rabbit
anti-human FHL1 antibody (1:1000, cross-reacting with the fourth
LIM domain [coded for by exon 4–6] of FHL1A, AVIVA Systems
Biology, San Diego, CA, USA) or polyclonal goat anti-human
Kv1.5 (1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) as primary antibodies (diluted in 3% (w/v) BSA). After
washing, the membranes were incubated (2 h, 25uC) with swine
anti-rabbit IgG (1:750) or donkey anti-goat IgG (1:2000) as
secondary antibodies (diluted in TBST containing 3% [w/v] non-
fat dry milk). Immunoreactive bands were visualised with
Immobilon Western Chemiluminescent HRP substrate (Millipore,
Billerica, MA, USA). For normalisation, membranes were stripped
with Restore
TM Western Blot Stripping buffer (Pierce) and
reprobed with anti-b-human actin antibody (1:1000, in 3% [w/
v] BSA, Santa Cruz) and goat anti-mouse IgG (1:2500, 1 h, 25uC,
Rockland, Gilbertsville, PA, USA) as secondary antibodies.
HL-1 cells transfection and confocal microscopy
FHL1C-p
eYFP-N1 (plasmid encoding for human FHL1C with
the enhanced yellow fluorescence protein fused to its C-terminus)
and Kv1.5-peYFP-N1 clones were raised using PCR technique and
suitable primers (Table S2; see below). The p
eCFP-C1+human
Kv1.5 construct (plasmid encoding for human Kv1.5 with the
enhanced cyan fluorescence protein fused to its N-terminus) was
kindly provided by Dr. Antonio Felipe (Barcelona, Spain).
Plasmids encoding for eCFP-labelled ß-subunit of the signal
recognition particle receptor Srß (Srß
eCFP) and the eCFP-labelled
glycosylphosphatidylinositol anchor domain (GPI
eCFP) were kindly
provided by Dr. Koret Hirschberg (Tel Aviv, Israel) and prepared
as described [24,25]. Srß
eCFP was used as an endoplasmic
reticulum marker while GPI
eCFP was used to label lipid raft
domains within the plasma membrane.
Transfection of HL-1 cells with the plasmids mentioned above
was performed with Lipofectamine according to the manufactur-
er’s suggestions. Cells were screened for signal 24 to 48 h after
transfection using confocal imaging using a Leica inverted
microscope with a laser-scanning module attached (DMIRE2
and TCS SL2; Leica Microsystems, Heidelberg, Germany). Using
the 636water immersion objective (NA: 1.20), confocal sections
(102461024 pixels) were obtained at 12-bit resolution. Filter
settings were: eYFP: excitation (514 nm); excitation beam splitter:
DD 458/514; emission (540–570 nm). eCFP: excitation (458 nm);
excitation beam splitter: DD 458/514; emission (477–500 nm).
Interference between eCFP and eYFP channels was negligible.
Analysis of confocal images was done using the ImageJ software
(ImageJ 1.42 h by Wayne Rasband, NIH, and Bethesda, MD)
supported with deconvolution plug-in (Bob Dougherty; http://
www.optinav.com/imagej.html).
Pull-Down assay
A DNA fragment encoding amino acid residues 518 to 613
(numbering according to human Kv1.5, NP_002225.2) was
synthesized by the PCR using a cDNA clone encoding full length
Kv1.5 (kindly provided by Dr. Joachim Ehrlich, Frankfurt am
Main, Germany) as a template and cloned into the vector pGEX-
4T-1 using suitable primers (Table S2). The recombinant protein
was heterologously expressed in E.coli and purified as described
[26]. Four hundred fifty ng cRNA encoding FHL1C (or Gb1 and
Gc2, respectively) were translated and radiolabelled in vitro using
9.4 ml rabbit reticulocyte lysate (Promega, Mannheim, Germany)
and 0.95 ml
35S-methionine (Amersham GE Healthcare) by
incubation at 37uC for 2 h. Purified GST-Kv1.5 fusion protein
(10–20 mg) was used as bait and incubated with 10 ml of lysate
containing
35S-labeled FHL1C in 300 ml buffer (25 mM HEPES-
Na, 5 mM MgCl2, 5 mM EGTA, 0.05% Tween-20 [v/v,
pH 7.0]), for 2 h at 25uC, with gentle rocking. GST protein
alone was used as a negative control (i.e. no binding to FHL1C
was expected). G-protein activated inwardly rectifying potassium
channel (GIRK1) C-terminus (G1-CT) was used both as a positive
control (in combination with
35S-labeled G-protein b subunits
(Gbc)) as well as a negative control (in combination with
35S-
labeled FHL1C lysate). Control proteins were prepared as
described [26]. Then, 30 ml of previously washed Glutathione
Sepharose beads were added, the mixture was incubated (30 min,
25uC) and then washed three times in 1 ml of the same buffer.
After washing, GST-fusion proteins were eluted with 30 mlo f
15 mmol/l reduced glutathione in elution buffer (120 mM NaCl,
100 mM Tris, 0.05% Tween-20 [v/v, pH 8]) and subjected to
12% linear SDS-PAGE. Radioactivity was quantified by autora-
diography of the dried gels, using a PhosphorImager Storm
TM
(GE Healthcare, Vienna, Austria). The amount of radioactivity
was normalized to the amount of protein of a given band, as
measured by staining of bands with Coomassie Brilliant Blue
(=relative specific radioactivity).
DNA constructs
For protein expression in Xenopus oocytes, FHL1C and Kv1.5
inserts were synthesized by PCR using suitable primers (Table S2)
and cloned into the pBSmxt oocyte expression vector. A full-length
FHL1C: A Binding Partner for Kv1.5
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Kv1.5-pcDNA3.1 (kindly provided by Joachim Ehrlich, Frankfurt,
Germany) were used as PCR templates. The resulting pBSmxt
constructs were linearized, cRNA was synthesized as described
[27], aliquots were shock frozen in liquid nitrogen and stored at
270uC until use. Integrity of all DNA constructs was verified by
DNA-sequencing (3130xl DNA Analyzer, Applied Biosystems,
Vienna, Austria). DNA was prepared by Qiagen midiprep kit and
concentration and purity was checked with Nanodrop (Thermo
Scientific, Waltham, MA, USA).
Xenopus oocytes expression and electrophysiology
Xenopus oocytes, prepared as described [28], were injected with
50 nl of the following RNAs (either alone or in combination): Kv1.5
(2 ng RNA/nl), FHL1C (50 or 500 ng RNA/nl). Oocytes were
incubated in ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM
CaCl2, 1 mM MgCl2, 5 mM HEPES/NaOH [pH 7.6]) supple-
mented with gentamycin (50 mg/ml) and sodium pyruvate
(2.5 mM) at 19uC. Three to seven days after injection of oocytes,
whole cell currents were recorded using agarose cushion electrodes
[29]. Kv1.5 channels were characterized by the following voltage
jump protocols: voltage-dependent activation was assessed by
keeping the oocytes at a resting potential of 280 mV and K
+
currents were elicited by consecutive voltage jumps repeated every
7 sec (from 235 mV to +45 mV in 5 mV increments). Inactiva-
tion of Kv1.5 was quantified by the ratio of the magnitude of K
+
current 1.8 sec after a suprathreshold pulse to +15 mV divided by
the peak current at this potential. Current traces were sampled at
300 msec sampling rate and low pass filtered at 500 kHz using a 4-
pole Bessel filter. Parameters were normalized to the ones obtained
from control oocytes (injected with cRNA encoding Kv1.5 alone)
for a given experimental day and batch of oocytes. Data
acquisition and analysis was performed using the digidata 1322A
interface and the pClamp 9.2 software (both Molecular Devices,
Sunnyvale, CA, USA).
Statistics
Each experiment was performed at least three times. Data of
representative experiments are expressed as mean 6 SD or 6
SEM. Experimental parameters were analyzed between groups
using Student’s t-test (Sigma plot for Windows, v11, Systat
Software). Means were checked for statistically significant
differences (* p,0.05, ** p,0.01, and *** p,0.001). Sequence
analysis and alignments were performed using Chromas Lite
(v2.01, Technelysium Pty Ltd).
Results
Myoblast proliferation and cell cycle distribution
A significant reduction in the number of viable myoblasts
isolated from both XMPMA patients when compared to controls
was observed in between 24 h and 72 h (Figure 2A). Although the
differences between WT and mutant myoblasts were statistically
significant up to 72 h, the differences between WT2 and MUT2
were less pronounced when compared to WT1 and MUT1. To
detect possible cell cycle alterations, FACS analyses were
performed. A significantly higher number of patient myoblasts
was found in the G0/G1 phase when compared to controls
Figure 2. Proliferation rate of human myoblasts. Myoblasts from controls (WT1, WT2) and patients (MUT1, MUT2) were cultured for the
indicated times (A) or for 48 h (B). Myoblast samples WT1 and MUT1 originated from tibialial anterior muscle biopsy, samples WT2 and MUT2 from
biceps brachii muscle biopsy. (A) Cell proliferation was determined by measuring the number of viable cells using Casy cell counter. Values represent
mean 6 SD of three experiments (six wells per one experiment). **p,0.01 and *** p,0.001. (B) Flow cytometric measurements (see Methods) were
performed to estimate cell cycle, i.e. G0/G1 phase, S phase, and M phase, respectively. One representative experiment (performed in triplicate) out of
three is shown.
doi:10.1371/journal.pone.0026524.g002
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patient myoblasts in the G0/G1 phase was 28% in MUT1
(p,0.001) but only 8% in MUT2 (p,0.001).
Expression of Kv1.5 and FHL1 in myoblasts of XMPMA
patients and controls
Expression of Kv1.5 on mRNA (Figure 3A) and protein level
(Figure 3B) was almost absent (MUT1) or decreased (MUT2) in
patient myoblasts, when compared to controls. Expression of total
FHL1 mRNA transcripts (coding for all known FHL1 isoforms
(FHL1A–C) is comparable between control and XMPMA
myoblasts (Figure 3A). While expression of FHL1A mRNA is
similar in control myoblasts (WT1 and WT2), it is remarkably
decreased (MUT1) or almost absent (MUT2) in XMPMA cells
(Figure 3A). In parallel, expression of mRNA encoding FHL1C
was found to be low (MUT1) or high (MUT2). This observation is
in line with the assumption that the production of mRNA
encoding for FHL1C is unaffected in MUT1 but apparently
increased in MUT2; this splice site mutation generates additional
mRNA encoding a truncated FHL1-like protein that is identical to
FHL1C.
Subsequently, FHL1 expression on the protein level was
investigated. Due to the lack of commercially available antibodies
against FHL1C only expression of FHL1A could be followed.
Western blot experiments demonstrated the presence of FHL1A in
myoblasts from controls while only trace amounts were present in
XMPMA patient myoblasts (Figure 3). Densitometric evaluation
of immunoreactive Kv1.5 and FHL1A bands is shown in Figure S1.
Subcellular localisation of FHL1C and Kv1.5
Since FHL1A (a protein containing four and the half LIM
domains) has recently been shown to interact with Kv1.5 [13], we
were interested whether FHL1C (lacking the two C-terminal LIM
domains being present in FHL1A) could behave in a similar
manner. First, we checked whether FHL1C colocalized with Kv1.5
in vivo. Fluorescently labelled Kv1.5 and FHL1C chimeras were
generated by PCR technique and the corresponding constructs
were expressed in atrial cells. Figure 3A shows pronounced
expression and predominant nuclear localization of FHL1C
eYFP
and, to a lesser extent, in the cytoplasm; these results partly parallel
previous findings when FHL1C (tagged with the green fluores-
cence protein) was expressed in a hepatoma cell line [12] or
embryonal fibroblasts [30]. On the other hand Kv1.5
eCFP was
predominantly localized within the cytoplasm with low fluores-
cence intensity in the nucleus.
The precise subcellular distribution of Kv1.5 and FHL1C was
studied by coexpression of both proteins with marker proteins
that localize within specific cellular compartments. Coexpres-
sion of Kv1.5
eYFP with Srß
eCFP revealed predominant localiza-
tion of the channel in the endoplasmic reticulum (Figure 4B).
Partial colocalization of Kv1.5
eYFP with GPI
eCFP is further
indicative for its additional presence in the plasma membrane
including lipid rafts (Figure 4C). Distribution of FHL1C
eYFP
showed considerable overlap with Srß
eCFP (Figure 4B) and
partial overlap with GPI
eCFP (Figure 4C), indicating that
substantial amounts of FHL1C localize intimately close to both
subcellular compartments. Intensity histograms (Figure 4A–C)
show the number of pixels in the images at each different
intensity value. During our exp e r i m e n t sw eh a v eo b t a i n e d
individual histograms for each signal (CFP and YFP, presented
in red or green) and the combination of both is shown
(Figure 4A–C). Although FHL1C and Kv1.5 exerted quite
different subcellular localization patterns as a whole, there was
substantial overlap within both the plasma membrane and the
endoplasmic reticulum, indicating that interaction of these
proteins is likely within a living cell.
Physical interaction between FHL1C and Kv1.5
Subsequently, it was of interest to investigate whether FHL1C
physically interacts with Kv1.5. As a positive control for protein/
protein interaction, the pull-down assay was performed using a
GST fusion of the cytosolic C-terminus of GIRK1 (isoform 1 of
the G-protein activated inwardly rectifying K
+ channel; a well
known direct G-protein effector) as bait and the G-protein ß1/c2
dimer (Gß/c) as binding partner [26]. As a negative control, i.e. no
specific protein/protein interaction, pull-down between GST
alone and Gß/c or FHL1C was performed. Although minimal
non-specific interaction of FHL1C with GST could be seen, when
compared to Gß/c (Figure 5, lane 2/3 vs. lane 1) considerable
physical interaction of FHL1C with the C-terminal portion of
Kv1.5 was clearly detected (Figure 5A/B, lane 4/5).
Figure 3. RT-PCR and Western blot for FHL1 and Kv1.5 in human
myoblasts. (A) RNA was isolated from myoblasts from controls (WT1,
WT2) and XMPMA patients (MUT1, MUT2) and the corresponding Kv1.5
and FHL1 regions were amplified by RT-PCR. Primers, spanning from
exon 1 to 2 (termed FHL1) amplify the mRNA stretch coding for the
common N-terminus of FHL1 in all three FHL1 isoforms (FHL1A, FHL1B
and FHL1C), while primers termed FHL1A or FHL1C specifically amplify
mRNAs encoding FHL1A or FHL1C, respectively. (P=positive control:
human fetal brain marathon cDNA). To ensure equal gel loading, RT-
PCR for human HPRT1 was performed. One representative experiment
out of three is shown. See Table S1 for the primer sequences used. (B)
Protein lysates from myoblasts from controls (WT1, WT2) and XMPMA
patients (MUT1, MUT2) were subjected to SDS-PAGE. Proteins were
transferred to nitrocellulose membranes and immunoreactive bands
were detected with anti-Kv1.5 or anti-FHL1A as primary antibodies. After
stripping, the membranes were incubated with anti-b-actin antibody.
(Kv1.5=68 kDa; FHL1A=32 kDa; b-actin=45 kDa). One representative
experiment out of three is shown.
doi:10.1371/journal.pone.0026524.g003
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heterologously expressed Kv1.5 channels
In order to test whether FHL1C exerts functional effects on
Kv1.5, both proteins were heterologously coexpressed in the
Xenopus laevis oocyte system. Functional characterization of Kv1.5
was performed by assessing its voltage-dependent activation. Most
remarkably, coexpression of FHL1C reduced Kv1.5 currents at all
potentials tested, when compared to oocytes expressing Kv1.5 alone
(Figure 6A and B). Such reduction in current magnitude could in
principle be brought about by either (i) effects of FHL1C
Figure 4. Subcellular localization of heterologous expressed chimaeric FHL1C and Kv1.5 constructs in the atrial HL-1 cell line. Cells
were cultured as described and after transfection, fluorescence of either eYFP- and eCFP-labelled proteins was detected as described in the Methods
section. Each horizontal sequence of images was taken from the same cell and vertical section. For better visualization of colocalization, the eYFP and
eCFP channels are shown in green and red, respectively, hence yellow in the overlay image indicates colocalization (merge). Intensity histograms are
shown to quantify colocalization of both markers (right). Histogram shows the pixel-by-pixel analysis of the section indicated by the yellow line in the
merged channel (from left to right). (A) Staining for FHL1C
eYFP and Kv1.5
eCFP and colocalization. (B) Staining for Kv1.5
eYFP (upper) and FHL1C
eYFP (lower)
and colocalization with Srß
eCFP (a marker for the endoplasmic reticulum). (C) Staining for Kv1.5
eYFP (upper) and FHL1C
eYFP (lower) and colocalization
with GPI
eCFP (a marker for lipid raft domains of the plasma membrane). One representative series of images out of three independent series of
experiments is shown.
doi:10.1371/journal.pone.0026524.g004
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channel inactivation) or (ii) interference of FHL1C with channel
biosynthesis and/or trafficking (resulting in reduced insertion of
Kv1.5 complexes into the plasma membrane). Parameters of
voltage-dependant activation and channel inactivation are shown
in Table 1. Steady-state activation (Figure 6B and C) was analyzed
by fitting the measured peak current (Ipeak) as a function of
membrane potential (Em) to a Boltzmann isotherm resulting in
corresponding values for reversal potential (Erev), potential for half-
maximal activation (E0.5), slope of Boltzmann distribution (k) and
the conductivity for K
+ ions at maximal activation (Gmax). Analysis
of voltage-dependent activation parameters revealed that neither
the potential of half-maximal activation nor the gating charge, i.e.
the steepness of the Boltzmann isotherm, was affected by FHL1C
(Figure 6C). Also Kv1.5 inactivation was apparently unchanged
upon coexpression with FHL1C (Figure 6D). In conclusion, all
analyzed parameters of channel kinetics did not alter when Kv1.5
was coexpressed with either low or high cRNA levels of FHL1C
(Table 1). Interestingly, the maximal conductance (Gmax) of the
oocytes for K
+ ions produced by Kv1.5 complexes was reduced
considerably and statistically significant upon FHL1C coexpres-
sion. This reduction was observed during the entire time-span
tested after cRNA injections (Figure 6E) and clearly correlated
with the amount of coinjected cRNA encoding FHL1C (Figure 6F).
Coexpression of oocytes with Kv1.5 and FHL1C reduced Gmax by
approx. 33% (50 ng FHL1C cRNA/nl) or approx. 75% (500 ng
FHL1C cRNA/nl) (Figure 6F).
Summarizing all data from Figure 6, we conclude that FHL1C
coexpression of Kv1.5 with FHL1C resulted in a reduced
membrane insertion of Kv1.5 complexes into the plasma
membrane, without influencing kinetics.
Discussion
Mutations in FHL1 (previously called skeletal muscle LIM
protein 1) cause distinct types of muscular dystrophies e.g.
XMPMA [2], which may be associated with cell cycle alterations
of myoblasts. We here show a reduced proliferation rate of
myoblasts from XMPMA patients; furthermore, an increased
number of myoblasts in the G0/G1 phase is paralleled by low
expression of Kv1.5.
Villalonga and coworkers [14] previously reported that Kv1.5 is
involved in skeletal muscle proliferation. In their studies [14] Kv1.5
was operative by controlling G1 phase progression through a
mechanism that involves the CDKIs p21
cip-1 and p27
kip1 as well as
cyclins A and D1. Our study provides additional evidence for a
possible involvement of Kv1.5 in myotube growth; however, the
aim of our study was to link myoblast proliferation, expression of
Kv1.5 and a possible interaction with FHL1C, a LIM-domain-
containing protein that is abundantly expressed in XMPMA.
Although a panel of different interacting proteins as well as
putative binding partners have been identified for FHL1 [31,32],
no data are available for FHL1C specifically. We here show for the
first time both, a physical and a functional interaction of Kv1.5 with
FHL1C.
A recent paper [33] reported that FHL1 knockdown signifi-
cantly inhibits proliferation of rat aortic smooth muscle cells.
Traffic and subcellular localization regulate ion channel activities
[34] and these conditions may affect both skeletal and cardiac
muscle tissues [6–9]. We here found that FHL1C is localized in the
nucleus and the cytoplasm, in the latter colocalizing with Kv1.5
that can be found mostly in the endoplasmic reticulum and the
plasma membrane. Our studies were performed in HL-1 cells, a
cellular model that retains important atrial features like contrac-
tility and excitability [18]. Our data is the first report on Kv1.5
expression in myoblasts from patients with a myopathy associated
with mutations in FHL1. The presence of intact FHL1C as
occurring in XMPMA patients might contribute to the relative
mild phenotype when compared to other FHL1 mutation-
associated myopathies [2]. We therefore could speculate that
FHL1C might compensate either absent or reduced levels of other
FHL1 isoforms.
Our in vitro data (pull-down assay) confirm a physical interaction
of Kv1.5 with FHL1C. From our observations, we may assume that
the two and a half N-terminal LIM domains in FHL1 are
responsible for effective interaction with Kv1.5. Previous genetic
analyses of XMPMA patients [6,9] suggested that FHL1C could
play a specific role in cardiomyophathy. In the present study we
show that in myoblasts from XMPMA patients (with specific
mutations in FHL1) FHL1C is expressed at mRNA levels
comparable to controls. However, due to degradation of FHL1A
(MUT1) or expression of a truncated FHL1C-like protein
Figure 5. Physical interaction of FHL1C with the Kv1.5 cytosolic
C-terminus. (A) Autoradiography of the dried gel, showing the
amount of radioactive protein associated with the bait. As radioactive
protein either FHL1C or the ß/c subunits of heterotrimeric G-protein
(Gß/c; control) was used as indicated at the bottom of the lanes. (B)
Commassie Brilliant Blue staining of the SDS gel shown in panel A. Bait
proteins used are indicated at the bottom of the lanes: GST protein
alone (GST); GST-Kv1.5 C-terminus fusion protein (Kv1.5); C-terminus of G-
protein activated inwardly rectifying potassium channel (GIRK1) fused
with GST (G1-CT) as positive control. (C) Statistics of the bound
radioactivity normalized to the amount of bait protein (relative specific
radioactivity) for FHL1C using Kv1.5 and GST as a bait (left) and Gß/c
using G1-CT and GST as a bait (right). Values represent the mean values
from different experiments (N is given in parenthesis above each bar).
Significant difference (**p,0.01) between GST and Kv1.5 /G1-CT.
doi:10.1371/journal.pone.0026524.g005
FHL1C: A Binding Partner for Kv1.5
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26524(MUT2), FHL1C is likely to increase on a percentage level when
compared to total FHL1 expression. Further studies performed in
the Xenopus oocyte system (Figure 5) demonstrate reduced
conductivity of Kv1.5 (Gmax) indicative for a reduced density of
the K
+ channel within the plasma membrane. This in turn
suggests that FHL1C could act as a scaffold protein that modulates
Kv1.5 trafficking to the plasma membrane. We therefore may
speculate that increased levels of FHL1C could be the cause for a
reduced current in the human atrium leading to enhanced atrial
fibrillation in further consequence. Kv1.5 has been reported to
interact with FHL1A [13]. The lack of this FHL1 isoform in
XMPMA patients could affect stability of Kv1.5. Unfortunately, to
date, no studies are available on atrial fibrillation and subsequent
heart failure in XMPMA patients.
Yang and coworkers [13] have recently reported that
coexpression of Kv1.5 with FHL1A in Chinese hamster ovary cells
resulted in increased currents compared to expression of Kv1.5
alone, findings that are in apparent contrast to our observations
coexpressing Kv1.5 and FHL1C in oocytes. This difference could
Figure 6. Coexpession of FHL1C reduces currents through Kv1.5 channels in Xenopus laevis oocytes. (A) Representative original current
traces recorded from two oocytes expressing either Kv1.5 alone (upper panel) or Kv1.5 in combination with FHL1C (lower panel). Each family of current
traces originated from four different suprathreshold voltage pulses (235, 210, +10 and +40 mV). Recordings were taken five days after cRNA
injection. (B) Ipeak/Em relation for the oocytes shown in (A). Original data (circles) and fit through the data according to a Boltzmann isotherm (solid
lines) are shown. (C) Representative statistics of steady-state activation (n‘) five days after cRNA injection (with and w/o 500 ng cRNA encoding
FHL1C coexpressed). Circles represent mean values 6 SEM from six batches of oocytes (five oocytes per batch and experimental condition) and the
dotted lines fits trough the data according to Boltzmann isotherms, respectively. (D) Kv1.5 inactivation kinetics, same data set as in C. Mean values of
the current inactivation ratio (ratio{15mV~
I(1:8s)
Ipeak
) 6 SEM are shown. (E) Time course of the effect of FHL1C coexpression on maximal K
+ conductance.
Data were normalized to Gmax of oocytes expressing Kv1.5 alone for five days (mean values 6 SEM of six different batches of oocytes are shown); at
least five oocytes were recorded from every batch and experimental group. (F) Dose dependent effect of coexpression of FHL1C on Gmax; five days
after cRNA injection. The amount of cRNA coinjected, encoding FHL1C, is shown at the bottom. Mean values 6 SEM from six different experiments
(five oocytes per batch and experimental group) is shown (ns: the difference is statistically not significant, *: p,0.05 and ***: p,0.001, respectively).
doi:10.1371/journal.pone.0026524.g006
Table 1. Effect of FHL1C coexpression on Kv1.5 kinetics:
reversal potential (Erev), potential of half-maximal activation
(E0.5), slope of Boltzmann isotherm (k) and channel
inactivation (ratio 215 mV).
Kv1.5
Kv1.5+FHL1C
(50 ng cRNA)
Kv1.5+FHL1C
(500 ng cRNA)
Erev (mV) 233.5865.71 236.4066.25 236.2366.20
E0.5 (mV) 21.3761.94 21.1161.53 21.4362.34
k( m V
21) 6.1460.12 6.5160.16 5.9560.17
ratio 215 mV 0.7660.05 0.7460.05 0.7160.04
Values are mean 6 SEM of six independent experiments ($5 oocytes were
analysed per experimental day).
doi:10.1371/journal.pone.0026524.t001
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lacks two LIM domains in the C-terminal portion) in oocytes
where a different processing/trafficking mechanism of FHL1
splice variants may occur. Such alternative processing/trafficking
has been reported already for FHL1C but translocation to the
nucleus may be mediated by particular protein modifications and/
or protein interactions [12,31]. Another explanation might be the
lack of a functional domain, RBP-Jk, in the C-terminal portion of
FHL1A (Figure 1). The RBP-Jk moiety, when complexed with the
signal-transducing Notch intracellular domain, may act as a
transcriptional activator [35], a process recently addressed to
occur in myocyte differentiation [36]. Most importantly, KyoT2,
the murine homolog of FHL1C, and Notch1 competes with each
other for binding to RBP-Jk [30]. Taken these structural elements
into account, different effects of the three main FHL1 isoforms on
channel activities may not be surprising at all.
In conclusion, we have described the interaction of FHL1C, a
specific FHL1 isoform, with Kv1.5. Since Kv1.5 expression and
functionality are altered in XMPMA patients we assume that
FHL1 might regulate channel in both cardiac and skeletal muscle.
Absence of FHL1 could result in lack of regulation of the channel
and explain at least a part of the (patho)physiology found in
XMPMA patients.
Supporting Information
Figure S1 Densitometric evaluation of FHL1A and Kv1.5
expression in human myoblasts. Immunoreactive bands
(shown in Figure 3B) were scanned and their intensity was
determined using ImageJ 1.40 g software from Wayne Rasband of
the National Institutes of Health (Bethesda, MD, USA). The
relative intensity of each band was calculated by dividing the
absolute intensity of the respective band by the absolute intensity
of the respective loading control band (b-actin). (A) Kv1.5
expression in control (WT1, WT2) and XMPMA patient
(MUT1, MUT2) myoblasts. Values for control samples are set
to 1 and for XMPMA patients normalized to corresponding
controls. Experiments were performed in triplicates (WT1 and
MUT1) and quadruplicates (WT2 and MUT2). (B) FHL1A
expression in myoblasts using the same samples as listed in (A).
Experiments were performed in triplicates.
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